Sem-VI (CBSGIS) = PC = II 2-11-16

QP Code: 21702

(3 Hours)

MICAL CAMPUS, IN [Total Marks: 70

- 1. Answer the following. Question 1-11 carry one mark each and questions 12-13 carry 2 marks each
 - 1. Give an example (structure and name) of a drug that is a nucleic acid analog with its therapeutic use.
 - 2. Which is the weakest among all the intermolecular bonding forces.
 - 3. What is a quaternary structure of a protein. Give an example
 - 4. An alpha helix is an example of a protein primary structure. True or False. Correct if False.
 - 5. Give an example of a monoclonal antibody's therapeutic use
 - 6. Which enzyme kinetic parameter/s do competitive inhibitors affect.
 - 7. Give the structure and name of a drug that is an antibacterial due to inhibition of a bacterial enzyme
 - 8. Give an example of a receptor that has autocatalytic activity.
 - 9. The DNA double helix is an example of DNA tertiary structure. True or False. Correct if False.
 - 10. Name a DNA intercalating agent and give its therapeutic use
 - 11. Cis and trans terms imply optical somerism. True or False. Correct if False.
 - 12. Give one example of a CYP+50 catalyzed metabolic reaction using a drug/chemical of your choice.
 - 13. Proteins can be drug targets or drugs themselves. Explain the statement
- (a) Discuss any four intermolecular forces involved in drug-receptor binding
 - (b) Answer the following (any two)
 - i. Explain the following terms:
 - a) Monoclonal antibodies
 - b) Proteomics
 - ii. Give the structure and chemical name of a sulfonamide used for ulcerative colitis
 - iii. Classify sulfonamides on the basis of duration of action giving one example from each class

[TURN OVER

LO-Con.: 446-15.

| | (c) | Give the structures and names of any three degradation products of penicillins | 3 |
|----|------|--|----|
| | | OR | |
| | (c) | Fill in the blanks: | 3 |
| | (0) | i. Introduction of ——— group which is electron ———, | 3 |
| | | at the α -carbon leads to acid stability in penicillins | - |
| | | ii. Introduction of a fluoro group at ———— position increases | 1 |
| | | the potency of quinolones | 0 |
| | | iii. Increasing the ———— is responsible for rendering the | 4 |
| | | penicillins β-lactamase resistant. | |
| | | | |
| 3. | | Classify receptors and give one example from each class. | 4 |
| | (b) | Answer in brief: | 4 |
| | | i. Explain the following terms. | |
| | | a. Agonist | |
| | | b. Potency | |
| | | ii. Give the structure, generic name and use for the following: | |
| | | 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl) quinoline- | |
| | | 3-carboxylic acid | |
| | (c) | Outline the various steps involved in the synthesis of primaquine. | -3 |
| 4. | (a) | Name any three Phase II drug metabolizing enzymes and give an | 4 |
| | | example of a reaction catalyzed by any one of them. | |
| | | Describe the synthesis of ampicillin OR cloxacillin | 3 |
| | (c) | Give reasons for the following: | |
| | | i. Drugs should have appropriate solubility and partition | 2 |
| | | coefficient for oral administration. | |
| | | ii. Sparflexacin is not phototoxic | 1 |
| | | iii. Co-trimoxazole is an example of synergism | 1 |
| ~ | | | |
| 5. | (a) | Discuss SAR of tetracycline with respect to position 5 and 6 of the | 3 |
| | (1-) | ring. | |
| | (0) | Outline the synthesis of PAS along with reagents and reaction | 3 |
| | (0) | Conditions. | • |
| | (6) | Write a note on artemisinin and improvements made to artemisinin | 3 |
| 17 | | OR | |

QP Code: 21702

LO-Con.: 446-15.